Carfilzomib: uses, dosing, side effects & brands
Carfilzomib is a proteasome inhibitor sold in the U.S. under 3 brand and generic names, for multiple myeloma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Drug class
- Proteasome Inhibitor
- Treats (across its forms)
- Multiple Myeloma
- Available as
- Powder · Injectable
- Sold as
- 3 products — Carfilzomib, Kitprozy and Kyprolis
- Prescription?
- Prescription only
- Generic available?
- Yes
How Kyprolis is dosed
From the FDA label for Kyprolis (application NDA202714). Other carfilzomib products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Hydrate prior to and following Kyprolis as needed. ( 2.1 ) Premedicate prior to all Cycle 1 doses and if infusion-related reactions develop or reappear. ( 2.1 ) The recommended dosing regimens are as follows. See Full Prescribing Information for additional dosage information. ( 2.2 ) Regimen Dosage Infusion Time Kyprolis and Dexamethasone (Kd) or Kyprolis, Daratumumab and Dexamethasone (DKd) or Kyprolis, Daratumumab and hyaluronidase-fihj and Dexamethasone (DKd) 20/70 mg/m 2 once weekly 30 minutes Kyprolis and Dexamethasone (Kd) or Kyprolis, Daratumumab and Dexamethasone (DKd) or Kyprolis, Daratumumab and hyaluronidase-fihj and Dexamethasone (DKd) or Kyprolis, Isatuximab and Dexamethasone (Isa-Kd) or Kyprolis Monotherapy 20/56 mg/m 2 twice weekly 30 minutes Kyprolis, Lenalidomide and Dexamethasone (KRd) or Kyprolis Monotherapy 20/27 mg/m 2 twice weekly 10 minutes 2.1 Administration Precautions Hydration Adequate hydration is required prior to dosing in Cycle 1, especially in patients at high-risk of tumor lysis syndrome (TLS) or renal toxicity. Consider hydration with both oral fluids (30 mL per kg at least 48 hours before Cycle 1, Day 1) and intravenous fluids (250 mL to 500 mL of appropriate intravenous fluid prior to each dose in Cycle 1). If needed, give an additional 250 mL to 500 mL of intravenous fluids following Kyprolis administration. Continue oral and/or intravenous…
Everything below is the FDA label for Kyprolis (injectable). Carfilzomib is also sold as powder, and those are different medicines to take — follow the label for the one you were prescribed.
Kyprolis side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Cardiac Toxicities [see Warnings and Precautions (5.1) ] Acute Renal Failure [see Warnings and Precautions (5.2) ] Tumor Lysis Syndrome [see Warnings and Precautions (5.3) ] Pulmonary Toxicity [see Warnings and Precautions (5.4) ] Pulmonary Hypertension [see Warnings and Precautions (5.5) ] Dyspnea [see Warnings and Precautions (5.6) ] Hypertension [see Warnings and Precautions (5.7) ] Venous Thrombosis [see Warnings and Precautions (5.8) ] Infusion-Related Reactions [see Warnings and Precautions (5.9) ] Hemorrhage [see Warnings and Precautions (5.10) ] Thrombocytopenia [see Warnings and Precautions (5.11) ] Hepatic Toxicity and Hepatic Failure [see Warnings and Precautions (5.12) ] Thrombotic Microangiopathy [see Warnings and Precautions (5.13) ] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions (5.14) ] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions (5.15) ] The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral. ( 6 ) The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in the combination therapy trials: anemia, diarrhea,…
Who shouldn’t take Kyprolis
None. None. ( 4 )
Every carfilzomib product we track (3)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Powder | No data | — | View → | |
| 2 | Not yet rated | Prescription | Injectable | No data | — | View → | |
| 3 | Not yet rated | Prescription | Injectable | No data | — | View → |
Carfilzomib and breastfeeding
From LactMed, the US National Library of Medicine’s Drugs and Lactation Database — quoted, not rewritten.
Full LactMed record for carfilzomib: levels in milk, effects in breastfed infants, and the drugs it would consider insteadNo information is available on the clinical use of carfilzomib during breastfeeding. Because carfilzomib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during carfilzomib therapy and for 2 weeks after the last dose.
National Institute of Child Health and Human Development, record revised September 21, 2020. LactMed states its information is not a substitute for professional judgement.
What people report to the FDA about carfilzomib
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 13,366 reports naming carfilzomib, and the FDA flagged 95% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- plasma cell myeloma1,928 reports
- thrombocytopenia1,097 reports
- pneumonia810 reports
- neutropenia778 reports
- anaemia747 reports
- pyrexia654 reports
- acute kidney injury627 reports
- diarrhoea509 reports
Read these as a signal, not a rate. A report does not mean carfilzomib caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is Kyprolis?
Kyprolis (Carfilzomib) is a proteasome inhibitor used to treat Multiple Myeloma.
What kind of drug is carfilzomib?
The FDA classifies carfilzomib as a proteasome inhibitor. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take carfilzomib with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run carfilzomib against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is carfilzomib sold under?
We track 3 carfilzomib-containing products in the U.S.: Carfilzomib, Kitprozy and Kyprolis. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does carfilzomib come in?
Across the brands we track, carfilzomib is currently marketed as powder and injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic carfilzomib?
Yes. Our catalog lists 1 generic carfilzomib product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.
Cite this page
- APA
- pharmaranks. (2026, July 24). Carfilzomib: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/carfilzomib
- MLA
- “Carfilzomib: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/carfilzomib.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for carfilzomib on DailyMed (NIH) ↗.